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Regulatory T cell (Treg) immunotherapy is a promising strategy for the treatment of graft rejection responses
and autoimmune disorders. Our and other laboratories have shown that the transfer of highly puriﬁed
CD4þCD25þFoxp3þ natural Treg can prevent lethal graft-versus-host disease (GVHD) after allogeneic
hematopoietic cell transplantation across both major and minor histocompatibility barriers. However, recent
evidence suggests that the Treg suppressive phenotype can become unstable, a phenomenon that can
culminate in Treg conversion into IL-17eproducing cells. We hypothesized that the intense proinﬂammatory
signals released during an ongoing alloreaction might redirect a fraction of the transferred Treg to the Th17
cell fate, thereby losing immunosuppressive potential. We therefore sought to evaluate the impact of Il17 gene
ablation on Treg stability and immunosuppressive capacity in a major MHC mismatch model. We show that
although Il17 gene ablation results in a mildly enhanced Treg immunosuppressive ability in vitro, such
improvement is not observed when IL-17edeﬁcient Treg are used for GVHD suppression in vivo. Similarly,
when we selectively blocked IL-1 signaling in Treg, that was shown to be necessary for Th17 conversion, we
did not detect any improvement on Treg-mediated GVHD suppressive ability in vivo. Furthermore, upon
ex vivo reisolation of transferred wild-type Treg, we detected little or no Treg-mediated IL-17 production
upon GVHD induction. Our results indicate that blocking Th17 conversion does not affect the GVHD
suppressive ability of highly puriﬁed natural Treg in vivo, suggesting that IL-17 targeting is not a valuable
strategy to improve Treg immunotherapy after hematopoietic cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Regulatory T cell (Treg) immunotherapy is a promising
strategy for the therapeutic control of both autoimmune
diseases and graft-versus-host responses. CD4þCD25þFoxp3þ
Treg cells are a key immunoregulatory cell population
involved in the maintenance of immune tolerance [1,2]. The
transfer of highly puriﬁed Treg has demonstrated promising
results in preclinical models for both the control of autoim-
munity [3,4], and the induction of transplantation tolerance
[5-8]. In particular, after allogeneic hematopoietic cell trans-
plantation (HCT), we and others have shown that Treg
successfully prevent lethal graft-versus-host disease (GVHD)
induced by donor-derived conventional T cells (CD4þ and
CD8þ T cells; Tcon) in multiple models across both major and
minor histocompatibility barriers [9-18].
GVHD is a potentially life-threatening complication after
HCT, where Tcon of alloreactive speciﬁcities inﬁltrate and
destroy healthy target organs such as the liver, gastrointes-
tinal tract, and skin. Although immunomodulation is neces-
sary to control adverse GVHD reactions, an effective immune
response is required for successful tumor eradication, termed
the graft-versus-tumor effect, and for the prevention ofedgments on page 1564.
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13.07.024opportunistic infections. Notably, when cotransferred into
recipient mice with established leukemia or lymphoma, Treg
suppressed Tcon proliferation and prevented lethal GVHD,
while preserving graft-versus-tumor activity [12,14,15,17].
Furthermore, extension of these ﬁndings to the clinic using
Treg from haploidentical or umbilical cord blood donors has
recently shown promising results [19,20].
The molecular basis for the suppressive activity of Treg is
still a matter of debate. An increasing body of evidence
suggests that, under the inﬂuence of certain inﬂammatory
signals, the Treg suppressive phenotype can become unstable,
and that Treg are capable of converting into IL-17eproducing
proinﬂammatorycells invivo and invitro [21-30]. Forexample,
Foxp3þIL-17þ intermediates have been detected both in vivo
and ex vivo in murine models for autoimmune encephalo-
myelitis [29] and diabetes [31]. While such plasticity of the
Treg phenotype is likely to be beneﬁcial during an ongoing
infection, it represents a major threat for the stability of Treg
suppressive function following Treg immunotherapy.
The role of IL-17 itself on GVHD progression is currently
controversial. In different experimental models, IL-17 has
been reported to be not necessary unecessary [32],
promoting [33], or ameliorating GVHD [34]. IL-17 production
by Tcon does not seem to represent a major pathogenic
factor, and the absence of donor-derived IL-17 was shown to
exacerbate rather than ameliorate GVHD across major
histocompatibility barriers, due to increased Th1 differenti-
ation [34]. We focused on evaluating the role of the Il17 gene
and IL-17 cytokine production on Treg phenotypic stabilityTransplantation.
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Figure 1. IL-17 KO Tregs have mildly enhanced suppressive ability on the
proliferation of allogeneic T cells in vitro. Tregs from WT or IL-17 KO donors
were compared for their suppressive ability in an MLR in vitro. Irradiated total
splenocytes from Balb/c mice (d/d haplotype) were used as stimulators (S) and
CD4þ and CD8þWT C57BL/6 mice (b/b haplotype) were used as responders (R)
at a ﬁxed 2:1 S/R ratio. At the same time, Treg isolated from either WT or IL-17
KO donors (both on a C57BL/6 background, b/b haplotype) were added at 1:1,
2:1, and 10:1 Tcon/Treg ratios. After 4 days of co-incubation, the cells were
pulsed with 1 mCi [3H]-thymidine per well for 16 to 18 hours and Tcon
proliferation was quantiﬁed by measuring [3H]-thymidine incorporation. The
bar graphs are representative of 2 different MLRs combined. Probability values
are as indicated, representing differences in suppressive function of the 2
populations of Treg.
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effort to improve Treg function for the control of GVHD
in vivo. Indeed, IL-17 production by Treg has been consis-
tently associated with a loss of their suppressive phenotype
[26,35,36]. Thus, we employed in vitro and in vivo systems to
assess the role of IL-17 targeting on Treg function for the
suppression of allospeciﬁc T cell activation.
METHODS
Mice
Il17a knockout mice were previously described [32] and were a kind gift
of Dr. DeFu Zeng, City of Hope National Medical Center (Duarte, CA), with
permission of Dr. Y. Iwakura, Institute for Medical Science (Tokyo, Japan).
Il1r1 KOmice (strain B6.129S7-Il1r1tm1Imx/J),WT C57BL/6 (Thy1.2þ), C57BL/6
Thy1.1þ, C57BL/6 CD45.1þ, andWT Balb/c micewere purchased from Jackson
Laboratories (Sacramento, CA). lucþ C57BL/6-L2G85 mice were previously
described [37,38]. All experimental animals were housed at the Stanford
University animal facility and used under Administrative Panel on Laboratory
Animal Care (APLAC)-approved protocols.
Mixed Lymphocyte Reactions
Balb/c splenocyteswere irradiated with 30 Gy and used as stimulators at
a 2:1 ratio with mixed CD4þ and CD8þ responder cells. CD4þ and CD8þ
responders were puriﬁed from pooled spleens and lymph nodes of C57BL/6
mice with the aid of anti-mouse-CD4 (clone L3T4) and anti-mouse-CD8 (Ly-
2) magnetically labeled antibodies and Magnetic Cell Separation (MACS)
technology (Miltenyi Biotec, Auburn, CA). Irradiated stimulator cells,
responder cells, and different doses of highly puriﬁed Tregs, which were
sorted from either wild-type (WT) or IL-17 KO C57BL/6 mice, were plated in
a ﬂat-bottom 96-well plate. Following 4 days of incubation, the cells were
pulsed with 1 mCi per well of [3H]-thymidine and harvested 16 to 18 hours
later onto ﬁltermembraneswith the aid of aWallac harvester (Perkin-Elmer,
Waltham, MA). The amount of incorporated [3H]-thymidine was measured
with a Wallac Betaplate counter (Perkin-Elmer).
GVHD Model and Assessment
Balb/c (H-2d) recipients and C57/Bl/6 (H-2b) donors were used as
previously described [9,15-17]. Animals were prepared with a lethal dose of
total body radiation (consisting of 2 doses of 4 Gy, 4 to 6 hours apart), fol-
lowed by donor-derived 5  106 T celledepleted bone marrow (TCD-BM) on
day 0. GVHD was induced by the injection of 5  105 magnetically puriﬁed
CD4þ and CD8þ lucþ Tcon on day 2 at a 2:1 CD4-to-CD8 ratio. CD4þ and
CD8þ lucþ Tcon were puriﬁed from pooled spleens and lymph nodes of lucþ
C57BL/6 mice with the aid of anti-mouse-CD4 (clone L3T4) and anti-mouse-
CD8 (Ly-2) magnetically labeled antibodies and MACS cell separation tech-
nology (Miltenyi Biotec). The experimental animals were assessed for Tcon
proliferation, survival, and weight scores on the indicated time points.
Bioluminescent Cell Imaging System
lucþ CD4þ and CD8þ Tcon were transferred into the MHC-mismatched
recipients 2 days after TCD-BM and Treg injections. The experimental
animals were monitored at the indicated time points following the injection
of the luciferase substrate, luciferin. The number of lucþ cells is directly
proportional to the number of photons detected by the bioluminescent
imaging (BLI) system (IVIS 7, IVIS 29, or IVIS Spectrum charge-coupled device
imaging system; PerkinElmer, Waltham, MA), allowing for an accurate
quantiﬁcation of Tcon proliferation, which gives ameasure of ongoing GVHD
[17,39]. Images were analyzed with Living Image software 2.5 (Xenogen).
Treg Puriﬁcation
Treg were ﬁrst enriched from pooled spleens and lymph nodes of donor
mice via allophycocyanin-conjugated anti-CD25 antibodies (clone PC61.5;
eBioscience, San Diego, CA) and magnetically labeled anti-APC beads (MACS
cell separation technology; Miltenyi Biotec). Subsequently, Treg were highly
puriﬁed as CD4þCD25bright cells via ﬂuorescence activated cell sorting (FACS)
(BD FACSAria III, BD Biosciences, San Jose, CA) and conﬁrmed to be more
than 98% CD4þCD25brightFoxp3þ by intracellular Foxp3 staining (clones
GK1.5, PC61.5, and FJK-16s for CD4, CD25, and Foxp3, respectively).
Intracellular Cytokine Assessment
Balb/c recipient mice received C57BL/6-derived TCD-BM and highly
puriﬁed Treg intravenously on day 0, followed by Tcon infusion on day 2 as
described above. Recipient mice were sacriﬁced 7 and 14 days following
Treg transfer. Mesenteric lymph nodes, pooled peripheral lymph nodes
(cervical, brachial, axillary, and inguinal nodes), and spleen were isolated,
and single cell preparations were restimulated with phorbol 12-myristate13-acetate (40 ng/mL) and ionomycin (92 mM) in presence of monensin (2
mM, Sigma-Aldrich, St. Louis, MO) for 5 hours. The cells were then stained for
surface markers, ﬁxed, permeabilized, and assessed for intracellular IL-17A
and Foxp3 expression with the aid of a mouse Foxp3 staining kit (eBio-
science). The following antibodies were purchased from BD Pharmingen
(San Diego, CA), eBioscience, or BioLegend (San Diego, CA): CD4 (GK1.5), CD8
(53-6.7), CD45.1 (A20), Thy-1.1 (OX-7), CD25 (PC61), H-2Kb (AF6-88.5),
Foxp3 (FJK-16s), IL-17 (TC11-18H10.1), and IFN-g (XMG1.2). Transferred Treg
were identiﬁed as live CD4þH-2bþThy1.2þCD45.1 cells, whereas Tcon were
identiﬁed as Th1.1þCD45.1þH-2bþ cells. Residual recipient hematopoietic
cells were excluded as Th1.1CD45.1H-2dþ, and donor BM-derived cells
were gated out as Thy1.1þCD45.1H-2bþ cells. FACS analysis was performed
with an LSR II (BD Biosciences).
Statistical Analysis
Differences in Kaplan-Meier survival curves were analyzed with the log
rank test. All other comparisons were performedwith the 2-tailed Student t-
test. P < .05 was considered statistically signiﬁcant.
RESULTS
IL-17eDeﬁcient Treg Show a Mildly Enhanced Suppressive
Ability on the Proliferation of Alloreactive T Cells In Vitro
Treg have been demonstrated to convert into IL-
17eproducing cells under different inﬂammatory conditions
[21-30]. We hypothesized that a percentage of Treg or
a speciﬁc Treg subset that are exposed to intense inﬂamma-
tory signals released during ongoing GVHD in vivo might be
redirected to a Th17 cell fate, thus losing immunosuppressive
potential. Therefore, we reasoned that Treg puriﬁed from
Il17a knockout (IL-17 KO) donor mice would have enhanced
immunomodulatory capacity compared with WT Treg, given
their inability to produce IL-17A (more commonly referred to
as IL-17).
We ﬁrst compared WT and IL-17 KO Treg for the ability to
suppress allogeneic Tcon proliferation in a mixed lympho-
cyte reaction in vitro. Balb/c (H-2d) derived irradiated stim-
ulators and C57BL/6 (H-2b) derived responders were
incubated in the presence or absence of graded doses of WT
and IL-17 KO Treg. Four days later, Tcon proliferation was
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17 KO Treg were efﬁcient in controlling Tcon proliferation at
a 1:1 Tcon/Treg ratio, and such ability was lost at a high 10:1
ratio, as expected (Figure 1). Interestingly, Treg lacking the
IL17 gene demonstrated a 2-fold increase in the suppression
of allogeneic Tcon proliferation compared with WT Treg at
the intermediate Tcon/Treg ratio of 2:1.
WT and IL-17 KO Treg Have Comparable GVHD
Suppressive Ability In Vivo
We puriﬁed Treg from both WT and IL-17 KO mice for the
comparison of their GVHD suppressive ability in vivo in dose
titration experiments. Similarly to our invitro experiments,we
tested the GVHD suppressive ability of Treg across major
histocompatibility barriers. Typically, we found that a dose of
5  105 Treg injected i.v. on day 0 is effective in suppressing
GVHD [15,17]. In preliminary experiments, we used a high (1:1
Tcon/Treg ratio), intermediate (2:1 Tcon/Treg ratio), and low
(4:1 Tcon/Treg ratio) dose of transferred Treg to monitor
differences in Tcon proliferation and GVHD progression
demonstrating a doseeresponse relationship between the
number of Treg injected and overall survival (data not shown).
To explore the role of IL-17 in Treg function, Balb/c recip-
ients underwent lethal irradiation and were transplanted
with 5  106 TCD-BM and either 5  105 (1:1 Tcon/Treg ratio)
or 1.25  105 Treg (4:1 Tcon/Treg ratio) isolated from either
WT or IL-17 KO C57Bl/6 donors. To monitor ongoing GVHD,
our laboratory has developed a bioluminescent imaging (BLI)
system that allows the in vivo visualization of T cell homing
and proliferation over time, without the necessity of killing
the experimental animals [17,39]. Speciﬁcally, 2 days after the
transfer of the TCD-BM and Treg, the recipient animals
received .5  106 CD4þ and CD8þ allogeneic Tcon puriﬁed
from luciferaseþ (lucþ) C57Bl/6 donors. Importantly, the
number of photons emitted by the lucþ Tconwas shown to be
directly proportional to the number of Tcon present in vivo
[17,39]. Thus, our in vivo BLI system provides a quantitative
assessment of T cell proliferation at different time points
in vivo, which gives a measure of ongoing GVHD.
WT and IL-17 KO Treg demonstrated comparable purity
(>98% Foxp3þ cells) and similar expression levels of both
Foxp3 and the Treg marker CD25 (IL-2Ra chain)
(Supplemental Figure 1). IL-17 KO Tregs had identical GVHD
suppressive ability when compared with WT Treg in vivo
(Figure 2A,B). The Tcon-derived BLI signal was similarly
suppressed by WT and IL-17 KO Treg at both the 1:1 and 4:1
Tcon/Treg ratios (Figure 2C,D), the latter ratio showing
a signiﬁcant loss in the GVHD suppressive ability by both sets
of Treg in the in vivo setting.
Selective IL-1 Signaling Blockade Does Not Enhance Treg-
Mediated GVHD Suppressive Ability In Vivo
IL-17A production is not the sole mechanism by which
Th17 cells exert their proinﬂammatory activity. For example,
Th17 cells also produce large amounts of the proinﬂammatory
cytokines IL-17F, IL-22, and IL-21 [40,41]. Thus, we sought to
conﬁrm the results obtained with the IL-17A KO Treg by
comparing WT Treg with Treg lacking the Il1r1 gene, which
were shown to be resistant to Th17 conversion in vivo and
in vitro [29,30]. Speciﬁcally, IL-1b signaling was shown to be
necessary for the differentiation of both human [42] and
mouse Th17 cells [29] as well as for the conversion of Treg to
Th17 cells in multiple murine models for autoimmune
diseases [24,29,30]. We compared the immunosuppressive
ability of Treg isolated from IL-1R1KOmice, unable to respondto either IL-1a or IL-1b signals [43], to that of WT Treg. We
reasoned that by interrupting IL-1 signaling selectively inTreg,
we would completely prevent Treg to Th17 conversion,
possibly stabilizing Treg immunosuppressive phenotype and
enhancing GVHD suppression. Nevertheless, similar to the
results obtained with the IL-17 KO Treg in vivo, the GVHD
inhibitory capacity of Treg isolated from IL-1R KO mice was
equivalent to that of WT Treg (Figure 3). No difference was
notedwhen comparing the survival (Figure 3A) andBLI signals
(Figure 3C) of mice recipients of high doses of eitherWTor IL-
1R KO Treg. The recovery of weight of mice recipients of WT
Treg revealed only a minor improvement compared with that
of mice recipients of IL-1R KO Treg at the lower Treg doses
(Figure 3B).
Only a Minority of Highly Puriﬁed Treg Converts into IL-
17eProducing Cells In Vivo
We then monitored whether we could detect the
conversion of Treg into IL-17eproducing cells upon ex vivo
reisolation of the transferred Treg and intracellular cytokine
staining. Similar to the above-described experiments, weﬁrst
transferred highly puriﬁedWTTreg into the BM-transplanted
recipients, and then induced GVHDby cotransferring puriﬁed
Tcon 2 days later. We monitored Treg to Th17 conversion in
the spleen and lymph nodes of the transplanted animals by
intracellular cytokine staining, with the aid of congenic
markers 7 and 14 days later. Speciﬁcally, the transferred Treg
were identiﬁed as CD4þCD45.1Thy1.2þH-2bþcells to distin-
guish them from the CD45.1Thy1.1þH-2bþ BM-derived cells,
the CD45.1þThy1.1þH-2bþ Tcon, and the CD45.1Thy1.1H-
2dþ residual recipient-derived hematopoietic cells. A signiﬁ-
cant proportion of CD4þ Tcon produced detectable IL-17
approximately 2 weeks after GVHD induction (Figure 4 and
Supplemental Figure 2).
Conversely, consistent with our in vivo GVHD suppression
experiments, we could detect little or no IL-17 production
upon ex vivo reisolation of the transferred Treg (Figure 4).
Interestingly, approximately 10% to 20% of the transferred
Tregs did lose Foxp3 expression during ongoing GVHD
(Figure4B).Not surprisingly,wedetecteda small increase in IL-
17eproducing cells among the Treg that lost Foxp3 expression
(Figure 4C). However, the proportion of IL-17eproducing cells
was low in both Foxp3þ and Foxp3low/neg subsets of the rei-
solated Treg (Figure 4C). Thus, freshly isolated and highly
puriﬁed Treg do not appear to convert into IL-17eproducing
cells in our model, suggesting that IL-17 production is not
a factor affecting Treg stability during ongoing GVHD.
DISCUSSION
We previously demonstrated that Treg-based immuno-
therapy is a promising strategy for the prevention of GVHD
after bone marrow transplantation [9,15-18]. However, the
stability of Treg have been questioned in different experi-
mental models, with multiple studies describing the conver-
sion of Treg into IL-17eproducing cells under the inﬂuence of
inﬂammatory stimuli [21-30]. Novel evidence has uncovered
a common developmental pathway shared by Treg and Th17
cells. Both cells types are dependent on transforming growth
factor-b for their development from naive T cells [44,45].
Furthermore, transcription factor interplay has been demon-
strated in Tregs and Th17 cells in different in vivo and in vitro
experimental models [24,46-48], revealing developmental
plasticity between the two T cell subsets. In particular,
antigen-activated naive T cells coexpress Foxp3 and RoRgs
upon exposure to transforming growth factor-b [47], which
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Figure 2. WT and IL-17 KO Treg have a comparable GVHD suppressive ability in vivo. (A) Survival curves of recipient mice transplanted with BM alone (BM), BM on
day 0 þ Tcon on day 2 (Tcon group), and BM cotransplanted with either WT or IL-17 KO Treg, followed by Tcon transplantation 2 days later (Treg group). Both 1:1 and
4:1 Tcon/Treg ratios are shown. Data are representative of 2 independent experiments (BM n ¼ 9, Tcon n ¼ 10; WT Tcon/Treg 1:1 n ¼ 6; WT Tcon/Treg 4:1 n ¼ 7; IL-17
KO Tcon/Treg 1:1 n ¼ 7; IL-17 KO Treg 4:1 n ¼ 7). Statistical differences between survival curves were calculated with a log rank test. For the 1:1 Tcon/Treg ratio: Tcon
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L. Colonna et al. / Biol Blood Marrow Transplant 19 (2013) 1557e15651560
L. Colonna et al. / Biol Blood Marrow Transplant 19 (2013) 1557e1565 1561represent the main transcription factors driving the differen-
tiation of Treg and Th17 cells, respectively.
Moreover, Foxp3 was shown to directly bind and inhibit
the Th17-driving transcription factors RoRgs and RoRa,
whereas Foxp3 itself is inhibited in a STAT3-dependent
manner once Th17 differentiation ensues [24,46,47,49].
However, although mature Treg were shown to convert into
IL-17eproducing cells under different inﬂammatory condi-
tions [21-30], to our knowledge, terminally differentiated
Th17 cells have never been demonstrated to convert into
Foxp3þ Treg in vivo. This suggests that Treg to Th17
conversion might be a unidirectional phenomenon that
could impact the suppressive ability of Treg in vivo. Although
such Treg plasticity is likely to be beneﬁcial upon infection
with extracellular pathogens and fungi, the one-way
conversion of Treg into IL-17eproducing cells could affect
the stability of Treg suppressive phenotype and function
during Treg immunotherapy in vivo. Thus, developing
strategies to block such conversion might enhance the bio-
logical activity of Treg in vivo.
A better understanding of Treg biology is pivotal for the
optimization of our preclinical protocols aimed to enhance
Treg-mediated GVHD suppressive ability in vivo. This
prompted us to evaluate whether Il17a gene ablation would
result in the stabilization of Treg suppressive phenotype
in vitro and in vivo. Our laboratory recently adapted our
preclinical model to ongoing clinical trials (Negrin, unpub-
lished results), and we and others [19,20] are currently
assessing the efﬁcacy of highly puriﬁed human Treg in
a clinical setting. Our ultimate goal is to translate the insights
obtained in our preclinical studies into novel therapeutic
strategies, with the idea of minimizing the risk of GVHD and
the use of immunosuppressive drugs after HCT, which
predispose transplanted patients to an increased risk of
opportunistic infections. Indeed, when cotransferred into
lethally irradiated mice recipient of TCD-BM and Tcon, Treg
resulted in enhanced immune reconstitution and increased
survival after challenge with viral pathogens [16], without
interfering with Tcon-mediated tumor clearance due to
a reduction in GVHD mediated damage to lymphoid tissues.
When we assayed the immunomodulatory capacity of
Treg in an MLR in vitro, IL-17 KO Treg demonstrated an
approximate 2-fold increase in their ability to control the
proliferation of allospeciﬁc Tcon in vitro (Figure 1). However,
such enhancement did not impact the in vivo activity of IL-17
KO Treg, which had comparable biological activity to WT
Treg in suppressing GVHD (Figure 2). Similarly, selective
blockade of IL-1 signaling in Treg, which has been shown to
be necessary for Th17 conversion [29,30], did not enhance
the ability of Treg to control GVHD progression in vivo
(Figure 3). Furthermore, when we monitored whether WT
Treg do in fact convert into IL-17eproducing cells in vivo, wethe 4:1 Tcon/Treg ratio: BM vs. Tcon P ¼ .0002; Tcon vs. WT Treg P ¼ .06; Tcon vs. IL-17
vs. IL-17 KO Treg P ¼ .08. (B) Weight curves of the same animals as in (A). For consisten
the last mouse in each given group expired Statistical differences between groups wer
BM vs. Tcon P < .0001; Tcon vs. WT Treg P < .0001; Tcon vs. IL-17 KO Treg P < .0001; B
ratio: BM vs. Tcon P < .0001; Tcon vs. WT Treg P ¼ .13; Tcon vs. IL-17 KO Treg P ¼ .03; W
P < .0001. (C) In vivo BLI images of representative animals showing the luminescent sig
GVHD, in the presence or absence of WT and IL-17-KO Tregs. Both 1:1 and 4:1 Tcon/Tr
a measure of ongoing GVHD. Shown are 1:1 and 4:1 Tcon/Treg ratios. Data are repres
1:1 n ¼ 6; IL-17 Tcon/Treg 1:1 n ¼ 7; WT Tcon/Treg 4:1 n ¼ 7; IL-17 KO Tcon/Treg 4:1
Student t-test. For the 1:1 Tcon/Treg ratio: BM vs. Tcon P ¼ .05; WT Treg vs. IL-17 KO T
Treg P ¼ .19; BM vs. IL-17 KO Treg P ¼ .12. For the 4:1 Tcon/Treg ratio: BM vs. Tcon P ¼ .
Treg P ¼ .54; BM vs. WT Treg P ¼ .08; BM vs. IL-17 KO Treg P ¼ .09.could detect little or no IL-17 production by WT Treg upon
GVHD induction (Figure 4). It remains possible that IL-
17edeﬁcient Treg may lead to different results and, possibly,
show an improvement of Treg function in a different bone
marrow transplantation model, such as a minor mismatched
model. Of note, we subjected our recipients to total body
irradiation and H-2-mismatched Tcon and BM trans-
plantation, which is characterized by high proinﬂammatory
cytokine production, named the “cytokine storm,” with high
levels of IL-6 and IL-1 [50,51], 2 of the major cytokines
driving Treg toTh17 conversion. Thus, we reasoned that if we
could not detect any Th17 conversion after total body irra-
diation regimen in a major MHC-mismatched model, it was
unlikely for us to obtain more promising results upon Treg-
speciﬁc IL-17 gene ablation in a minor mismatch model.
Natural Treg represent a heterogeneous population,
a portion of which has been consistently shown to be
unstable and to lose Foxp3 expression under inﬂammatory
conditions, from where the name “ex Treg” [52]. In line with
these observations, approximately 10% to 20% of the trans-
ferred Tregs lost Foxp3 expression during acute GVHD
(Figure 4B). Becasue we did not note any functional differ-
ences between IL-17 deﬁcient and IL-17 sufﬁcient Treg, we
did not attempt to quantify in detail the numbers of IL-17
sufﬁcient versus IL-17 KO ex Treg after GVHD induction.
Thus, the phenotypic stability and Foxp3 expression proﬁles
of IL-17edeﬁcient Treg remain yet to be characterized.
Because of the low number of cells obtained upon ex vivo
reisolation, we could not assess whether such Treg losing
Foxp3 expression have impaired ability to suppress T cell
proliferation in vitro or GVHD in vivo. However, our in vitro
studies indicate that Foxp3 down-regulation is indeed
associated with a loss of Treg suppressive ability in vivo.
Further, prior studies using the immunosuppressive drug
cyclosporine A resulted in a reduction of Treg in vivo func-
tion, associated with a reduction in Foxp3 expression that
could be overcome by exogenous IL-2 [53].
Our results argue that despite a mild increase in their
ability to control the proliferation of allogeneic Tcon in vitro,
IL-17 targeting does not improve Treg-mediated control of
GVHD responses in vivo. We believe the slight improvement
in the Treg function seen in vitro is not sufﬁcient to be
translated to the in vivo setting, as GVHD develops after
sustained activation of a much more complex set of cytokine
cascades and of different cellular subsets than those acti-
vated in a short-term in vitro assay. Indeed, our in vivomodel
involves GVHD induction across major histocompatibility
barriers, where a cytokine storm [51] likely interferes with
the mildly enhanced suppressive ability of IL-17 KO Treg, the
result appearing to be comparable with that seen with WT
Treg. The mild improvement in the Tcon suppressive ability
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Figure 4. WT Treg do not produce IL-17 after GVHD induction in vivo. (A) TCD-BM cells and Treg were cotransplanted on day 0 after lethal irradiation, followed by
Tcon 2 days later (d þ2). The animals were sacriﬁced 7 and 14 days after BM transplantation (5 and 12 days post-GVHD induction), and lymphoid organs were
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CD4þCD45.1þThy1.1þH-2bþ. Donor BM cells and residual recipient hematopoietic cells (H-2dþ) were gated out as CD45.1Thy.1.1þH-2bþ and CD45.1Thy1.1H-2dþ
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L. Colonna et al. / Biol Blood Marrow Transplant 19 (2013) 1557e1565 1563
L. Colonna et al. / Biol Blood Marrow Transplant 19 (2013) 1557e15651564complete lack of IL-17 exposure in the donor mice. However,
to our knowledge, there is no report describing an increase in
the suppressive function of Treg isolated from IL-17 KO mice.
Our study did not address the impact of Treg-speciﬁc IL-17
gene inactivation on Tcon to Treg conversion. It has been
suggested that human IL-17eproducting Treg may be
instrumental in controlling Th17-mediated inﬂammation by
responding to the same inﬂammatory chemoattractants,
allowing speciﬁc suppression of Th17 cell activation at the
site of inﬂammation [54]. Thus, the study on Tcon to Treg
conversion in presence or absence of Treg-produced IL-17 is
in need of further investigation.
Overall, our results argue that most highly puriﬁed Treg do
not convert into IL-17eproducing cells during an ongoing
alloreaction invivo, suggesting that IL-17and/or IL-1b targeting
are not likely to be productive strategies to improve Treg
immunotherapy after allogeneic HCT. We performed our
experiments with freshly isolated CD4þCD25bright natural Treg
and therefore cannot exclude that IL-17 deﬁciencymay lead to
a functional advantage upon in vitro expansion. Because
Treg abundance is a major issue for Treg immunotherapy in
human patients, the functional assessment of IL-17 KO Treg
after in vitro expansion is worthy of further investigation.
Further studies are needed to attempt to stabilize the Treg
suppressive phenotype and prevent Foxp3 loss after the
transfer of puriﬁed Treg and GVHD induction in vivo. In an
effort to optimize Treg immunotherapy after HCT, we are
currently assessing the efﬁcacy of Treg that lack speciﬁc
inhibitory molecules and of Tregs that have been expanded
and activated in vitro or in vivo with the use of particular
immunosuppressive medications or cytokines. Importantly,
if successful, Treg immunotherapy may be extended to
further clinical applications, such as tolerance induction in
the context of severe autoimmune diseases and/or solid
organ transplantation.
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